A single drug and multiple study failures leave Anavex with nothing but cash
By Adam Feuerstein Jan. 2, 2024
It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-101
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.35 |
Change
0.070(0.57%) |
Mkt cap ! $1.578B | |||
| Open | High | Low | Value | Volume |
| $12.25 | $12.45 | $12.02 | $7.808M | 638.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 41 | $12.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.37 | 1579 | 2 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |